PubMed Health⌕ Search

PubMed · 14688448

Classifying hepatitis B virus genotypes.

Abstract

In 1988, hepatitis B virus (HBV) was classified into four genotypes by a sequence divergence in the entire genome exceeding 8%, and designated by capital letters of the alphabet from A to D. There are seven genotypes of HBV (A-G) at present, and an eighth is on the horizon. They have an uneven geographical distribution, and only a few of them are prevalent in a given area of the world. Thus genotype A is frequent in northwest Europe, Sub-Saharan Africa, India and the North, Central and South America, B as well as C are common in Southeast Asia and Oceania, and D is prevalent in the Mediterranean area, Central Asia and South America. Genotype E is restricted to West Africa, and F is localized in Central and South America. The distribution of genotype G added to the alphabet list very recently has yet to be determined. Coinfection with HBV of distinct genotypes is not infrequent and found in about 10% of infected individuals, and is responsible for intertypic recombination of HBV genomes. The mutation for a stop codon in the precore region (G1896A) for aborting the translation of hepatitis B e antigen (HBeAg) is prohibited in HBV genomes of genotype A, as well as some of genotypes C and F, because they possess C at position 1858 that makes a Watson-Crick pair with G at position 1896. Hence, seroconversion to antibody to HBeAg is forbidden or delayed in individuals who carry them. Evidence is accumulating as regards the influence of HBV genotypes on the progression of chronic hepatitis B and response to antiviral therapies. HBV isolates even of the same genotype can differ in virological and clinical characteristics, and therefore, the genotype needs to be classified further into subtypes, especially if they are clinically relevant.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yuzo Miyakawa, Masashi Mizokami. 2003. Classifying hepatitis B virus genotypes.. https://doi.org/10.1159/000074988

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The interleukin-6 -174 promoter polymorphism is associated with extrapulmonary bacterial dissemination in Streptococcus pneumoniae infection.

Interleukin-6 (IL-6) is required for the clearance of bacteria in pneumococcal pneumonia. The abundance of endogenous IL-6 production on infectious stimuli is associated with genotypic differences in the -174 promoter region of IL-6 (-174 G-->C), showing increased IL-6 levels in patients carrying the GG genotype. One hundred patients with culturally proven pneumococcal disease were analyzed for distribution of the G-/C-alleles in the IL-6 -174 promoter region in comparison to 50 age-matched controls. Extrapulmonary pneumococcal dissemination, including septic metastasis, endocardial and meningeal infection, was used as parameter for impaired clearance of the bacteria. No significant differences in the allele distribution were observed between patients and controls. Within the patient group, the interleukin-6 GG homozygous carriers were less likely to develop extrapulmonary pneumococcal infection (10.3% versus 30.9%; OR 0.26, 95% CI 0.07-0.94, p=0.04). The IL-6 GG genotype, encoding for enhanced IL-6 secretion on bacterial stimuli, reduces the risk of bacterial spread to extrapulmonary sites in pneumococcal infection, possibly due to a more effective clearance of the pathogen from the blood and the respiratory tract.

Genotype↗

A review on the design and reporting of studies on drug-gene interaction.

OBJECTIVE: Methodological standards for clinical pharmacogenetic studies should be developed to improve reporting of studies and facilitate their inclusion in systematic reviews. The essence of these studies lies within the concept of effect modification. STUDY DESIGN AND SETTING: A narrative review discussing methodological issues in the design and reporting of pharmacogenetic studies. RESULTS: Studying effect modification within a trial leads to the comparison of subgroups based on genotype. Differences in effect based on genotype should preferably be expressed in absolute terms (risk differences) to facilitate clinical decisions on treatment. Information on the distribution of potential effect modifiers or prognostic factors should be available to prevent a biased comparison of differences in effect between genotypes. The distribution of genotypes should also be presented and compared to Hardy-Weinberg equilibrium to check for selection bias. Additional points of interest include the possibility of selective nonavailability of biomaterial and the choice of a statistical model to study effect modification. CONCLUSION: Additional methodological issues should be taken into account when designing and reporting pharmacogenetic studies, to ensure high study quality. We present several important issues for future studies investigating drug-gene interactions that can serve as a basis for further discussion on methodology in pharmacogenetics.

Genotype↗

Standardization of the nomenclature for genetic characteristics of wild-type rubella viruses.

The main goals of the meeting--to provide guidelines for describing the major genetic groups of rubella virus and to establish uniform genetic analysis protocols--were achieved. Guidelines for describing the genotypes as an operational taxonomic group consisted of the designation of reference viruses and reference sequences for 7 genotypes of rubella viruses representing 2 clades, and designation of an additional 3 provisional genotypes. Provisional genotype status was given either because reference viruses were not yet available and/or because there was uncharacterized complexity within the genetic group. Uniform analysis protocols recommended the comparison of unknown viral sequences with the complete set of designated reference viruses, and recommended a minimum acceptable sequence window which produced phylogenetic results with high confidence values. A list of literature references about rubella virus phylogeny and molecular epidemiology is available from the WHO Internet site for this report. As additional understanding of the genetic characteristics of wild-type rubella viruses is achieved, updates to the recommended nomenclature will be made and published in the Weekly Epidemiological Record.

Genotype↗